Persistence at 12 months with denosumab in postmenopausal women with osteoporosis: interim results from a prospective observational study

Autor: Bradley S. Stolshek, S. Siddhanti, Irene Ferreira, David L. Kendler, P.R. Ho, Stuart L. Silverman, Deborah T. Gold, Christine Simonelli, Alexandra Papaioannou, A. Balasubramanian, C. Recknor, D. Belazi, E. M. Lewiecki, Jacques P. Brown, Ethel S. Siris, P. Dakin

Publikováno v: Osteoporosis International

Summary To determine persistence with subcutaneous denosumab every 6 months in women being treated for osteoporosis, we conducted a single-arm prospective, observational study in the United States and Canada. Among 935 patients enrolled, 12-month per

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ecdaf5819d41b96da4d60503d43c3161
http://europepmc.org/articles/PMC4286624

Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: Efficacy and safety results from a randomized open-label study

Autor: Irene Ferreira, M. Micaelo, S. Siddhanti, John D. Wark, M. Stone, Nikolaos Papaioannou, Lorenz C. Hofbauer, Jacques P. Brown, C. Roux, Astrid Fahrleitner-Pammer, M. C. Zillikens, P.R. Ho, Rachel B. Wagman, Federico Hawkins, Salvatore Minisola

Publikováno v: Bone, 58, 48-54. Elsevier Inc.

Denosumab has been shown to reduce new vertebral, nonvertebral, and hip fractures in postmenopausal women with osteoporosis. In subjects who were treatment-naive or previously treated with alendronate, denosumab was associated with greater gains in b

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f45728d30dd64af8a2ba16eded3d96a9
https://doi.org/10.1016/j.bone.2013.10.006

Effects of Diet Intakes on Metal and Electrolyte Distributions in Vital Organs

Autor: C.K. Daniels, Alex W. K. Chan, M.J. Minski, Solomon W. Leung, S. Siddhanti, B. Williams, James C. K. Lai

Publikováno v: Procedia Environmental Sciences. 2:92-97

The intake and concentration of metals and electrolytes from our diet are believed to be affecting our general health, in particular, the proper functions of vital organs. For example, in addition to other genetic and environmental factors, consuming

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cdfca281fb73e574692069a1fb2923bf

Preference and satisfaction with a 6-month subcutaneous injection versus a weekly tablet for treatment of low bone mass

Autor: L. Bessette, S. F. Varon, Rachel B. Wagman, D. Macarios, David L. Kendler, Henry G. Bone, C. D. Hill, H.-S. Man, Rob Horne, Jeffrey T. Borenstein, H. Wang, S. Siddhanti, Deborah T. Gold

Publikováno v: Osteoporosis International. 21:837-846

The Preference and Satisfaction Questionnaire (PSQ) compares patient preference and satisfaction between a 6-month subcutaneous injection and weekly oral tablet for treatment of bone loss. Patients preferred and were more satisfied with a treatment t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d65d580e337ab30138d91bf501c7aa94
https://doi.org/10.1007/s00198-009-1023-x

A 24-month study evaluating the efficacy and safety of denosumab for the treatment of men with low bone mineral density: Results from the ADAMO trial

Autor: S. Siddhanti, Henry G. Bone, E. Michael Lewiecki, Roland Chapurlat, Edward Czerwiński, Bente L. Langdahl, Alan Kivitz, Ugis Gruntmanis, Bo Abrahamsen, P.R. Ho, Michael R. McClung, Rachel B. Wagman, Y.-C. Yang, Faisal M. Mirza, Michael A. Bolognese, Östen Ljunggren, Christence S. Teglbjaerg, Jean-Yves Reginster, David L. Kendler, Eric S. Orwoll, Paul D. Miller

Publikováno v: Langdahl, B L, Teglbjaerg, C S, Ho, P-R, Chapurlat, R, Czerwinski, E, Kendler, D L, Reginster, J-Y, Kivitz, A, Lewiecki, E M, Miller, P D, Bolognese, M A, McClung, M R, Bone, H G, Ljunggren, Ö, Abrahamsen, B, Gruntmanis, U, Yang, Y-C, Wagman, R B, Mirza, F, Siddhanti, S & Orwoll, E 2015, ' A 24-month Study Evaluating the Efficacy and Safety of Denosumab for the Treatment of Men With Low Bone Mineral Density : Results From the ADAMO Trial ', Journal of Clinical Endocrinology and Metabolism, vol. 100, no. 4, pp. 1335–1342 . https://doi.org/10.1210/jc.2014-4079
Langdahl, B L, Teglbjaerg, C S, Ho, P-R, Chapurlat, R, Czerwinski, E, Kendler, D L, Reginster, J-Y, Kivitz, A, Lewiecki, E M, Miller, P D, Bolognese, M A, McClung, M R, Bone, H G, Ljunggren, Ö, Abrahamsen, B, Gruntmanis, U, Yang, Y-C, Wagman, R B, Mirza, F, Siddhanti, S & Orwoll, E 2015, ' A 24-month Study Evaluating the Efficacy and Safety of Denosumab for the Treatment of Men With Low Bone Mineral Density : Results From the ADAMO Trial ', Journal of Clinical Endocrinology and Metabolism, pp. jc20144079 . https://doi.org/10.1210/jc.2014-4079

Context: One in 4 men in the United States aged >50 years will have an osteoporosis-related fracture. Fewer data are available on osteoporosis treatment in men than in women. Objective: The purpose of this study was to evaluate denosumab therapy in m

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20da2c31e9f294348537f6c1eccbe1f2
https://acuresearchbank.acu.edu.au/item/8833y/a-24-month-study-evaluating-the-efficacy-and-safety-of-denosumab-for-the-treatment-of-men-with-low-bone-mineral-density-results-from-the-adamo-trial